• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Hologic Inc.

    8/1/24 3:58:43 PM ET
    $HOLX
    Medical Electronics
    Health Care
    Get the next $HOLX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001748821
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    HOLOGIC INC
    SEC File Number
    001-36214
    Address of Issuer
    250 CAMPUS DRIVE
    MARLBOROUGH
    MASSACHUSETTS
    01752
    Phone
    5082632900
    Name of Person for Whose Account the Securities are To Be Sold
    COHN BENJAMIN JORDAN
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    5093417573.5923227190608/01/2024
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common12/29/2017ESPP PurchaseIssuerCheckbox not checked19812/29/2017Cash
    Common11/05/2018Restricted Stock VestingIssuerCheckbox not checked64111/05/2018Compensation
    Common06/30/2020ESPP PurchaseIssuerCheckbox not checked39406/30/2020Cash
    Common12/31/2020ESPP PurchaseIssuerCheckbox not checked7712/31/2020Cash
    Common06/30/2021ESPP PurchaseIssuerCheckbox not checked24406/30/2021Cash
    Common12/31/2021ESPP PurchaseIssuerCheckbox not checked10612/31/2021Cash
    Common06/30/2022ESPP PurchaseIssuerCheckbox not checked24306/30/2022Cash
    Common11/08/2022Restricted Stock VestingIssuerCheckbox not checked49511/08/2022Compensation
    Common11/09/2022Restricted Stock VestingIssuerCheckbox not checked51611/09/2022Compensation
    Common11/11/2022Restricted Stock VestingIssuerCheckbox not checked77411/11/2022Compensation
    Common12/30/2022ESPP PurchaseIssuerCheckbox not checked9112/30/2022Cash
    Common11/07/2023Restricted Stock VestingIssuerCheckbox not checked28611/07/2023Compensation
    Common11/08/2023Restricted Stock VestingIssuerCheckbox not checked51311/08/2023Compensation
    Common11/09/2023Restricted Stock VestingIssuerCheckbox not checked51511/09/2023Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    08/01/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Jared Cook, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Benjamin Cohn

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $HOLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HOLX

    DatePrice TargetRatingAnalyst
    1/12/2026Buy → Hold
    Argus
    1/5/2026$78.00Outperform → In-line
    Evercore ISI
    11/21/2025$79.00Outperform → Neutral
    BNP Paribas Exane
    10/7/2025$78.00In-line → Outperform
    Evercore ISI
    8/18/2025$80.00Hold → Buy
    Argus
    8/6/2025$87.00Sector Perform → Outperform
    RBC Capital Mkts
    7/9/2025$80.00Neutral → Buy
    Citigroup
    5/27/2025Hold
    Needham
    More analyst ratings

    $HOLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio

    Expanded FDA approval across multiple cervical cancer screening modalities supports clinical flexibility and provider choice Hologic, Inc. (NASDAQ:HOLX) announced today that its Aptima® HPV Assay received FDA approval for clinician-collected HPV primary screening. Hologic's human papillomavirus (HPV) test is the only FDA-approved mRNA-based assay, designed specifically to detect infections most likely to lead to cervical cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126336815/en/ Screening for cervical cancer is critically important to women's health. In the United States, it is estimated that in 2026, approximatel

    2/4/26 8:15:00 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic Announces Financial Results for First Quarter of Fiscal 2026

    – Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases (9.2%), Non-GAAP Diluted EPS of $1.04 Up 1.0% – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal first quarter ended December 27, 2025. The Company reported revenue of $1,047.8 million, GAAP diluted EPS of $0.79, and non-GAAP diluted EPS of $1.04. Highlights The Company has scheduled for February 5, 2026 a special meeting of stockholders to vote on adopting the merger agreement with funds managed by Blackstone and TPG, and related matters. Revenue of $1,047.8 million increased 2.5% for the quarter, or 1.3% on a constant currency basis. Total organic reve

    1/29/26 4:02:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Bedside Breakthrough: AI Brings MRI-Precision to Every Clinic

    ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD. USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 16, 2026 /PRNewswire/ -- The medical imaging world is hitting a massive reset button as AI-driven clinical intelligence transforms how we map the human heart. With the medical image management market projected to hit $9.06 billion by 2032[1], the era of bulky, multi-million dollar hardware is giving way to agile, software-defined diagnostics. As point-of-care tools accelerate toward a $70.92 billion market[2], hospitals are trading dedicated MRI suites for bedside intelligence that delivers hospital-grade precision on a portable device. This seismic shift is placing a massive premium on the

    1/16/26 11:56:00 AM ET
    $BFLY
    $GEHC
    $HOLX
    Medical Electronics
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $HOLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 29, 2024 - FDA Roundup: October 29, 2024

    For Immediate Release: October 29, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA responded to objections on the agency’s final rule that removed the authorized food contact uses of most phthalates because industry abandoned these uses. The FDA evaluated the objections and concluded that they did not provide a basis for mod

    10/29/24 3:30:19 PM ET
    $HOLX
    Medical Electronics
    Health Care

    February 2, 2024 - FDA Roundup: February 2, 2024

    For Immediate Release: February 02, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a safety communication to warn consumers, health care providers, and health care facilities not to use certain Cardinal Health Monoject luer-lock and enteral syringes. Dimensional changes made to the syringes, when used with syringe pump

    2/2/24 3:58:21 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    SEC Filings

    View All

    SEC Form 8-K filed by Hologic Inc.

    8-K - HOLOGIC INC (0000859737) (Filer)

    2/6/26 8:00:17 AM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form 10-Q filed by Hologic Inc.

    10-Q - HOLOGIC INC (0000859737) (Filer)

    1/29/26 4:08:35 PM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form DEFA14A filed by Hologic Inc.

    DEFA14A - HOLOGIC INC (0000859737) (Filer)

    1/29/26 4:04:16 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hologic downgraded by Argus

    Argus downgraded Hologic from Buy to Hold

    1/12/26 9:02:06 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Hologic from Outperform to In-line and set a new price target of $78.00

    1/5/26 8:48:38 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic downgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane downgraded Hologic from Outperform to Neutral and set a new price target of $79.00

    11/21/25 8:06:35 AM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Madaus Martin D bought $300,760 worth of shares (5,445 units at $55.24) (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    5/9/25 4:39:33 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SVP, Human Resources De Walt Diana covered exercise/tax liability with 4,416 shares, decreasing direct ownership by 37% to 7,603 units (SEC Form 4)

    4/A - HOLOGIC INC (0000859737) (Issuer)

    2/3/26 5:11:14 PM ET
    $HOLX
    Medical Electronics
    Health Care

    SVP, Human Resources De Walt Diana covered exercise/tax liability with 4,416 shares, decreasing direct ownership by 37% to 7,603 units (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    2/3/26 4:19:26 PM ET
    $HOLX
    Medical Electronics
    Health Care

    President, GYN Surgical Schnittker Brandon covered exercise/tax liability with 90 shares, decreasing direct ownership by 0.51% to 17,512 units (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    12/16/25 4:51:54 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hologic Inc.

    SC 13G/A - HOLOGIC INC (0000859737) (Subject)

    11/14/24 1:28:29 PM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form SC 13G filed by Hologic Inc.

    SC 13G - HOLOGIC INC (0000859737) (Subject)

    2/14/24 10:04:34 AM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form SC 13G/A filed by Hologic Inc. (Amendment)

    SC 13G/A - HOLOGIC INC (0000859737) (Subject)

    2/9/23 11:22:19 AM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Financials

    Live finance-specific insights

    View All

    Hologic Announces Financial Results for First Quarter of Fiscal 2026

    – Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases (9.2%), Non-GAAP Diluted EPS of $1.04 Up 1.0% – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal first quarter ended December 27, 2025. The Company reported revenue of $1,047.8 million, GAAP diluted EPS of $0.79, and non-GAAP diluted EPS of $1.04. Highlights The Company has scheduled for February 5, 2026 a special meeting of stockholders to vote on adopting the merger agreement with funds managed by Blackstone and TPG, and related matters. Revenue of $1,047.8 million increased 2.5% for the quarter, or 1.3% on a constant currency basis. Total organic reve

    1/29/26 4:02:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic to Announce Financial Results for the First Quarter of Fiscal 2026 on Thursday, January 29, 2026

    Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2026 on Thursday, January 29, after the market closes. As previously announced, in light of Hologic's pending acquisition by Blackstone and TPG, the Company will not be hosting a quarterly conference call or providing financial guidance. About Hologic Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com. SOURCE: Hologic, Inc. View source version on businesswire.com: https://www.businesswire.com/

    1/15/26 7:00:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic Announces Financial Results for Fourth Quarter of Fiscal 2025

    – Revenue of $1,049.5 Million Grows 6.2% – – GAAP Diluted EPS of $0.83 Increases 9.2%, Non-GAAP Diluted EPS of $1.13 Up 11.9% – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal fourth quarter ended September 27, 2025. The Company reported revenue of $1,049.5 million, GAAP diluted EPS of $0.83, and non-GAAP diluted EPS of $1.13. Highlights On October 21, 2025, the Company announced it had entered into a definitive agreement to be acquired by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share (the "Proposed Transaction"). Revenue of $1,049.5 million increased 6.2% for the quarter, or 5.4% in constant currenc

    11/3/25 4:01:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Leadership Updates

    Live Leadership Updates

    View All

    Biote Announces CEO Retirement and Succession Plan

    Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

    1/30/25 4:10:00 PM ET
    $BTMD
    $HOLX
    $MYGN
    Medicinal Chemicals and Botanical Products
    Health Care
    Medical Electronics
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    CellMax Life Announces Expansion of Company Board With Leading Industry Experts

    Renowned industry experts join to aid in preparation around premarket approval for FirstSight SUNNYVALE, Calif., April 6, 2023 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the appointment of Stanley N. Lapidus (Stan) as an advisory board member and Ronnie (Ron) Andrews as an independent board member. The announcement comes only one month after CellMax Life expanded its GI advisory board with luminaries in the GI arena. "Both Stan and Ron are pioneers in the diagnostics industry, with unique perspectives and proven track records of success," said Atul Sharan, CEO of CellMax Life. Stan is one of t

    4/6/23 9:00:00 AM ET
    $EXAS
    $HOLX
    Medical Specialities
    Health Care
    Medical Electronics

    IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS

    MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders.  "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics.  "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo

    11/11/21 7:26:31 PM ET
    $BEAT
    $GMED
    $GTHX
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Electronics